Medtronic Awarded $250 Mil., May Seek Injunction On Boston Sci Catheters
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will seek either injunctive relief or future royalties for several Boston Scientific angioplasty products after a federal jury found May 27 that the devices infringe Medtronic patents
You may also be interested in...
Medtronic v. Boston Scientific
Federal court in Marshall, Texas, finds that two of the three Medtronic patents allegedly infringed upon by certain Boston Scientific balloon angioplasty catheters and stent delivery systems are unenforceable due to "inequitable conduct" by Medtronic, Boston Scientific announces Aug. 29. A jury previously found that 10 of the Boston Scientific devices infringed Medtronic's Anderson and Fitzmaurice patents, and awarded $250 million in damages, later reduced to $186 million (1"The Gray Sheet" June 2, 2008, p. 16). As a result of the Aug. 29 decision, the damages were further reduced to $19 million. However, Boston Scientific says it plans to appeal the award in Washington, D.C., federal appeals court. Medtronic also says it is evaluating an appeal
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.